Showing 1 to 2 of 2 results


Esteve Acquires Caprelsa, Advancing Specialized Therapy Strategy
Esteve, a Barcelona-based pharmaceutical company, announced the acquisition of Caprelsa, a thyroid cancer treatment, from Sanofi on Monday, furthering its strategy to specialize in highly specialized therapies, fueled by a €1 billion investment from Lubea in 2023. This follows several other acquisit...
Esteve Acquires Caprelsa, Advancing Specialized Therapy Strategy
Esteve, a Barcelona-based pharmaceutical company, announced the acquisition of Caprelsa, a thyroid cancer treatment, from Sanofi on Monday, furthering its strategy to specialize in highly specialized therapies, fueled by a €1 billion investment from Lubea in 2023. This follows several other acquisit...
Progress
32% Bias Score

J&J acquires Intra-Cellular Therapies for $14.6 Billion
Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion, gaining control of Caplyta, a drug for schizophrenia and bipolar depression, with projected sales exceeding $1 billion in 2024 and $2.5 billion by 2028; the deal is expected to close later this year.

J&J acquires Intra-Cellular Therapies for $14.6 Billion
Johnson & Johnson is acquiring Intra-Cellular Therapies for $14.6 billion, gaining control of Caplyta, a drug for schizophrenia and bipolar depression, with projected sales exceeding $1 billion in 2024 and $2.5 billion by 2028; the deal is expected to close later this year.
Progress
36% Bias Score
Showing 1 to 2 of 2 results